Literature DB >> 19396168

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Brett S Carver1, Jennifer Tran, Anuradha Gopalan, Zhenbang Chen, Safa Shaikh, Arkaitz Carracedo, Andrea Alimonti, Caterina Nardella, Shohreh Varmeh, Peter T Scardino, Carlos Cordon-Cardo, William Gerald, Pier Paolo Pandolfi.   

Abstract

Chromosomal translocations involving the ERG locus are frequent events in human prostate cancer pathogenesis; however, the biological role of aberrant ERG expression is controversial. Here we show that aberrant expression of ERG is a progression event in prostate tumorigenesis. We find that prostate cancer specimens containing the TMPRSS2-ERG rearrangement are significantly enriched for loss of the tumor suppressor PTEN. In concordance with these findings, transgenic overexpression of ERG in mouse prostate tissue promotes marked acceleration and progression of high-grade prostatic intraepithelial neoplasia (HGPIN) to prostatic adenocarcinoma in a Pten heterozygous background. In vitro overexpression of ERG promotes cell migration, a property necessary for tumorigenesis, without affecting proliferation. ADAMTS1 and CXCR4, two candidate genes strongly associated with cell migration, were upregulated in the presence of ERG overexpression. Thus, ERG has a distinct role in prostate cancer progression and cooperates with PTEN haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396168      PMCID: PMC2835150          DOI: 10.1038/ng.370

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  25 in total

1.  ADAMTS1 proteinase is up-regulated in wounded skin and regulates migration of fibroblasts and endothelial cells.

Authors:  Monika Krampert; Sandra Kuenzle; Shelley N-M Thai; Nathan Lee; M Luisa Iruela-Arispe; Sabine Werner
Journal:  J Biol Chem       Date:  2005-04-20       Impact factor: 5.157

2.  Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

Authors:  Y E Whang; X Wu; H Suzuki; R E Reiter; C Tran; R L Vessella; J W Said; W B Isaacs; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

3.  The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.

Authors:  Manit Arya; Hitendra R H Patel; Claire McGurk; Roger Tatoud; Helmut Klocker; John Masters; Magali Williamson
Journal:  J Exp Ther Oncol       Date:  2004-12

4.  SIR2 and SIR4 interactions differ in core and extended telomeric heterochromatin in yeast.

Authors:  S Strahl-Bolsinger; A Hecht; K Luo; M Grunstein
Journal:  Genes Dev       Date:  1997-01-01       Impact factor: 11.361

5.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

6.  Tumor cell-specific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: A possible metastasis preventing and minimizing approach.

Authors:  Yifei Xing; Mei Liu; Yuefeng Du; Feng Qu; Yangsheng Li; Qingwei Zhang; Yajun Xiao; Jun Zhao; Fuqing Zeng; Chuanguo Xiao
Journal:  Cancer Biol Ther       Date:  2008-11-26       Impact factor: 4.742

7.  Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process.

Authors:  C A Hart; M Brown; S Bagley; M Sharrard; N W Clarke
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

8.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

Authors:  Jennifer C King; Jin Xu; John Wongvipat; Haley Hieronymus; Brett S Carver; David H Leung; Barry S Taylor; Chris Sander; Robert D Cardiff; Suzana S Couto; William L Gerald; Charles L Sawyers
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

9.  Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN.

Authors:  I C Gray; L M Stewart; S M Phillips; J A Hamilton; N E Gray; G J Watson; N K Spurr; D Snary
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

10.  Pten dose dictates cancer progression in the prostate.

Authors:  Lloyd C Trotman; Masaru Niki; Zohar A Dotan; Jason A Koutcher; Antonio Di Cristofano; Andrew Xiao; Alan S Khoo; Pradip Roy-Burman; Norman M Greenberg; Terry Van Dyke; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  PLoS Biol       Date:  2003-10-27       Impact factor: 8.029

View more
  319 in total

Review 1.  Genomic rearrangements in prostate cancer.

Authors:  Christopher E Barbieri; Mark A Rubin
Journal:  Curr Opin Urol       Date:  2015-01       Impact factor: 2.309

2.  HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.

Authors:  Imran Ahmad; Rachana Patel; Lukram Babloo Singh; Colin Nixon; Morag Seywright; Robert J Barnetson; Valerie G Brunton; William J Muller; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

3.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

4.  Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.

Authors:  Justin M Drake; Nicholas A Graham; Tanya Stoyanova; Amir Sedghi; Andrew S Goldstein; Houjian Cai; Daniel A Smith; Hong Zhang; Evangelia Komisopoulou; Jiaoti Huang; Thomas G Graeber; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

5.  Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells.

Authors:  Mahandranauth A Chetram; Valerie Odero-Marah; Cimona V Hinton
Journal:  Mol Cancer Res       Date:  2010-11-12       Impact factor: 5.852

Review 6.  New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.

Authors:  Göran Stenman; Mattias K Andersson; Ywonne Andrén
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

Review 7.  The role of mechanistic factors in promoting chromosomal translocations found in lymphoid and other cancers.

Authors:  Yu Zhang; Monica Gostissa; Dominic G Hildebrand; Michael S Becker; Cristian Boboila; Roberto Chiarle; Susanna Lewis; Frederick W Alt
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

8.  SPINK1 protein expression and prostate cancer progression.

Authors:  Richard Flavin; Andreas Pettersson; Whitney K Hendrickson; Michelangelo Fiorentino; Stephen Finn; Lauren Kunz; Gregory L Judson; Rosina Lis; Dyane Bailey; Christopher Fiore; Elizabeth Nuttall; Neil E Martin; Edward Stack; Kathryn L Penney; Jennifer R Rider; Jennifer Sinnott; Christopher Sweeney; Howard D Sesso; Katja Fall; Edward Giovannucci; Philip Kantoff; Meir Stampfer; Massimo Loda; Lorelei A Mucci
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

9.  Falling from grace: HPRT is not suitable as an endogenous control for cancer-related studies.

Authors:  Michelle H Townsend; Abigail M Felsted; Zac E Ence; Stephen R Piccolo; Richard A Robison; Kim L O'Neill
Journal:  Mol Cell Oncol       Date:  2019-02-26

Review 10.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.